Eventide Asset Management, LLC Adc Therapeutics Sa Transaction History

Eventide Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.92 - $5.45 $391,680 - $1.11 Million	-204,000 Reduced 10.85%	1,675,959 $3.27 Million
Q2 2022 Aug 15, 2022	SELL	$5.96 - $14.99 $566,444 - $1.42 Million	-95,041 Reduced 4.81%	1,879,959 $14.9 Million
Q4 2021 Feb 14, 2022	BUY	$19.29 - $31.51 $12.8 Million - $20.9 Million	663,010 Added 50.53%	1,975,000 $39.9 Million
Q2 2021 Aug 16, 2021	BUY	$20.38 - $27.04 $8.1 Million - $10.7 Million	397,251 Added 43.43%	1,311,990 $31.9 Million
Q1 2021 May 14, 2021	SELL	$22.75 - $34.05 $3.65 Million - $5.46 Million	-160,261 Reduced 14.91%	914,739 $22.3 Million
Q4 2020 Feb 16, 2021	BUY	$25.26 - $38.02 $12.5 Million - $18.8 Million	494,517 Added 85.19%	1,075,000 $34.4 Million
Q3 2020 Nov 13, 2020	BUY	$32.87 - $51.05 $14.1 Million - $22 Million	430,483 Added 286.99%	580,483 $19.2 Million
Q2 2020 Aug 14, 2020	BUY	$29.65 - $46.81 $4.45 Million - $7.02 Million	150,000 New	150,000 $7.02 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $135M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.